Present therapeutic approaches do not effectively target metastatic cancers, often limited by
their inability to eliminate already-seeded non-proliferative, growth-arrested, or therapy …

In recent decades, using circulating tumor cell (CTC), circulating tumor DNA (ctDNA),
circulating tumor RNA (ctRNA), exosomes and etc. as liquid biomarkers has received …

Background Chronic stress promotes most hallmarks of cancer through impacting the
malignant tissues, their microenvironment, immunity, lymphatic flow, etc. Existing studies …

Advances in the development of anti-HER2 monoclonal antibodies (mAbs) represent one of
the most significant milestones in the treatment of HER2+ breast cancer patients. However …

Triple-negative breast cancer (TNBC) is ineligible for hormonal therapy and Her-2-targeted
therapy due to the negative expression of the estrogen receptor, progesterone receptor, and …

Breast cancer (BC) is the first worldwide most frequent cancer in both sexes and the most
commonly diagnosed in females. Although BC mortality has been thoroughly declining over …

Tumor cell extravasation across endothelial barrier has been recognized as a pivotal event
in orchestrating metastasis formation. This event is initiated by the interactions of …

Breast cancer (BC) is the most frequently diagnosed cancer and one of the major causes of
cancer death. Despite enormous progress in its management, both from the therapeutic and …

We propose an original strategy for metastasis prevention using a combination of three
microRNAs that blocks the dedifferentiation of cancer cells in a metastatic niche owing to the …

Although the frequency of bone metastases from breast cancer has increased, effective
treatment is lacking, prompting the development of nanomedicine, which involves the use of …